Description
ESPENTRAL-LS is a fixed-dose combination designed for effective management of gastroesophageal reflux disease (GERD), dyspepsia, and associated motility disorders. It combines the potent acid-suppressing action of Esomeprazole with the prokinetic and antiemetic benefits of Levosulpiride.
Levosulpiride (75 mg SR)
-
-
A substituted benzamide derivative with selective dopamine D₂ receptor antagonistic activity.
-
Enhances gastrointestinal motility and gastric emptying.
-
Exhibits antiemetic, prokinetic, and antidepressant properties.
-
Esomeprazole (40 mg)
-
-
A proton pump inhibitor (PPI) that irreversibly inhibits H⁺/K⁺-ATPase in gastric parietal cells.
-
Provides sustained acid suppression, promotes mucosal healing, and relieves acid-related symptoms.
Indications
ESPENTRAL-LS is indicated for
Gastroesophageal Reflux Disease (GERD)
Non-ulcer dyspepsia
Functional dyspepsia with delayed gastric emptying
Nausea and vomiting associated with reflux disease
Peptic ulcer disease (as adjunct therapy)
Chronic gastritis with motility disorder
-
